Abstract There are still substantial clinical challenges in treating patients who come with type 2 diabetes and/or obesity in addition to chronic kidney disease (CKD)
278 , E1010E1018 (2000)
In the published Phase 2 obesity trial, people taking retatrutide 12mg lost an average of 24.2% of their body weight at 48 weeks, compared with 2.1% with placebo
Once in use, storage requirements vary by product: Ozempic (semaglutide): Up to 6 weeks at or below 30C Wegovy (semaglutide): Up to 28 days at or below 30C Trulicity (dulaglutide): Up to 14 days at or below 30C Victoza/Saxenda (liraglutide): Up to 30 days at or below 30C Always consult your specific product's patient information leaflet or pharmacist for guidance, as storage requirements differ between brands
It is available only through clinical trials or, in some jurisdictions, compounding pharmacies operating under specific protocols [12]
In the Phase 2 trial published in the New England Journal of Medicine in 2023, investigators assigned participants to placebo or to weekly amounts of 1 mg, 4 mg, 8 mg, or 12 mg over 48 weeks investigational quantities given under supervision
.webp)
